Acquisition of DEFIBROTIDE 200 MG/2.5 ML INJECTION SOLUTION
About This Opportunity
TranslatedThis tender pertains to the acquisition of DEFIBROTIDE in a concentration of 200 MG per 2.5 ML, intended for injection. DEFIBROTIDE is a medication used primarily in the treatment of conditions such as hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem cell transplantation. The procurement is aimed at ensuring the availability of this critical medication for healthcare providers. Key requirements for bidders may include the provision of relevant certifications, compliance with pharmaceutical regulations, and the ability to deliver the product within specified timelines. The tender is likely to be issued by a governmental health agency or a hospital network, emphasizing the importance of quality and reliability in the supply chain. Interested parties should prepare to demonstrate their capacity to meet the demands of this tender, including adherence to safety standards and competitive pricing. The location of service delivery will be specified in the tender documents, and bidders are encouraged to review all terms and conditions carefully to ensure compliance. This acquisition is crucial for maintaining the treatment protocols for patients requiring DEFIBROTIDE, thereby supporting public health initiatives.
This is a supplies contract in the health and medical services, information and communication technology and trade and industry sectors, with a focus on Pharmaceuticals, artificial intelligence and Manufacturing. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 153,360.
Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Original language: PortugueseThe tender titled "Aquisição de DEFIBROTIDO 200 MG/2.5 ML SOL INJ" is part of a public procurement process in Portugal, specifically aimed at acquiring a pharmaceutical product essential for medical treatment. DEFIBROTIDO is utilized primarily in the management of vascular conditions, making it a critical component in healthcare settings.
This tender is issued under the auspices of Portugal's public procurement framework, which is centralized through the Portal BASE, a platform designed to provide comprehensive information on public contracts across the mainland and autonomous regions of the country. The procurement process seeks to identify qualified suppliers capable of providing DEFIBROTIDO in the specified dosage of 200 mg/2.5 ml for injection use.
Prospective bidders are expected to demonstrate compliance with regulatory standards governing pharmaceutical products in Portugal, including adherence to Good Manufacturing Practices (GMP). Suppliers should possess necessary certifications and licenses that affirm their ability to distribute medical products within the European market. Additionally, bidders may be required to submit documentation outlining their experience in pharmaceutical supply, product availability, and delivery capabilities.
Timely delivery and competitive pricing will also be crucial evaluation criteria, as the contracting authority aims to secure a reliable source of this medication for healthcare facilities. Overall, this tender represents an opportunity for pharmaceutical companies to engage in the Portuguese healthcare sector, contributing to the effective provision of essential medical treatments.
Data provenance
This notice is sourced from base_gov_pt and was originally published on February 11, 2026. Last refreshed 8 days ago. Original language: Portuguese. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About Unidade Local de Saúde de São José, EPE
Unidade Local de Saúde de São José, EPE has issued 811 procurement notices on BidsFactory, including 18 currently open and 588 awarded contracts. Activity concentrates in Health & Medical, General Supplies & Services, and Information & Communication Technology. All notices are published for Portugal. Notices are distributed via base_gov_pt and TED - Tenders Electronic Daily (EU). Most recent publication: June 26, 2026.
Frequently asked questions about this tender
Who is the contracting authority?
This notice was issued by Unidade Local de Saúde de São José, EPE in Portugal. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
What is the estimated budget?
The estimated contract value is Up to €153,360. Bidders should ensure their proposals are consistent with this range and account for any local taxes and contract execution costs.
Where will the contract be performed?
The contract is for delivery in Portugal. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit base_gov_pt to access the full notice, required documents, and submission instructions provided by the contracting authority.
Is this tender still open?
No — the contract has already been awarded to JAZZ PHARMACEUTICALS FRANCE - SUCURSAL EM PORTUGAL. The award notice is archived on BidsFactory for transparency and market intelligence.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.